Education
About Us
Working with TipRanks
Follow Us
BrightPath Biotherapeutics Co.Ltd. (JP:4594)
:4594
RESEARCH TOOLSreports
4594 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥32.00 - ¥96.00
Previous CloseN/A
Volume188.00K
Average Volume (3M)14.82M
Market Cap
¥7.13B
Enterprise Value¥8.73B
Total Cash (Recent Filing)¥1.30B
Total Debt (Recent Filing)¥500.00M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding111,391,300
10 Day Avg. Volume7,181,490
30 Day Avg. Volume14,816,146
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)6.55
Price to Sales (P/S)0.00
P/FCF Ratio-8.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥49.00Price Target Upside-22.22% Downside
Rating ConsensusHold
Number of Analyst Covering0
4594 FAQ
What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?
BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥32.00 and its highest was ¥96.00 in the past 12 months.
What is BrightPath Biotherapeutics Co.Ltd.’s market cap?
BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥7.13B.
When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?
BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date is Aug 08, 2025 which is in 14 days.
How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?
BrightPath Biotherapeutics Co.Ltd. released its earnings results on May 09, 2025. The company reported -¥3.82 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.82.
Is BrightPath Biotherapeutics Co.Ltd. overvalued?
According to Wall Street analysts BrightPath Biotherapeutics Co.Ltd.’s price is currently Overvalued.
Does BrightPath Biotherapeutics Co.Ltd. pay dividends?
BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.
What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?
BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?
BrightPath Biotherapeutics Co.Ltd. has 111,391,300 shares outstanding.
What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?
BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥3.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?
Currently, no hedge funds are holding shares in JP:4594
Company Description
BrightPath Biotherapeutics Co.Ltd.
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.
Technical Analysis
Trans Genic Inc.
―
Immuno-Biological Laboratories Co., Ltd.
―
Ribomic, Inc.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―